抗凝药物的最新进展与市场分析
Recent progress and market analysis of anticoagulant drugs.
作者信息
Fan Ping, Gao Yangyang, Zheng Minglin, Xu Ting, Schoenhagen Paul, Jin Zhaohui
机构信息
Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China.
Imaging Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
出版信息
J Thorac Dis. 2018 Mar;10(3):2011-2025. doi: 10.21037/jtd.2018.03.95.
Abstract
This review describes epidemiology of thromboembolic disease in China and abroad, evaluates trends in the development of anticoagulant drugs, and analyzes the market situation based on large amounts of accumulated data. Specifically, we describe advances in clinical application of anticoagulants and analyze the most commonly used anticoagulants in the market systematically.
摘要
本综述描述了国内外血栓栓塞性疾病的流行病学，评估了抗凝药物的发展趋势，并基于大量积累的数据分析了市场情况。具体而言，我们描述了抗凝剂临床应用的进展，并系统分析了市场上最常用的抗凝剂。
相似文献
1
Recent progress and market analysis of anticoagulant drugs.抗凝药物的最新进展与市场分析
J Thorac Dis. 2018 Mar;10(3):2011-2025. doi: 10.21037/jtd.2018.03.95.
2
A Cost Variation Analysis of Drugs Available in the Indian Market for the Management of Thromboembolic Disorders.印度市场上用于治疗血栓栓塞性疾病的药物成本差异分析
Cureus. 2020 May 5;12(5):e7964. doi: 10.7759/cureus.7964.
3
Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment.患有抗磷脂抗体和静脉血栓形成的患者应接受长期抗凝治疗。
Ann Rheum Dis. 1993 Sep;52(9):689-92. doi: 10.1136/ard.52.9.689.
4
5
Anticoagulant and fibrinolytic drugs - possible agents in treatment of lung cancer?抗凝和纤溶药物——治疗肺癌的可能药物？
Anticancer Agents Med Chem. 2012 Jul;12(6):580-8. doi: 10.2174/187152012800617687.
6
[Extended anticoagulant treatment of venous thromboembolic disease with direct oral anticoagulants].[直接口服抗凝剂用于静脉血栓栓塞性疾病的延长抗凝治疗]
Semergen. 2018 Oct;44(7):500-503. doi: 10.1016/j.semerg.2018.05.004. Epub 2018 Jul 7.
7
Recent advances in anticoagulant drug delivery.抗凝药物递送的最新进展。
Expert Opin Drug Deliv. 2016;13(3):421-34. doi: 10.1517/17425247.2016.1125880. Epub 2015 Dec 23.
8
[The slow acceptance of new oral anticoagulants in Italy: a critical analysis of a problem].[新型口服抗凝剂在意大利的缓慢接受情况：对一个问题的批判性分析]
G Ital Cardiol (Rome). 2017 Mar;18(3):208-218. doi: 10.1714/2674.27398.
9
Advances in monitoring anticoagulant therapy.监测抗凝治疗的进展。
Adv Clin Chem. 2019;90:197-213. doi: 10.1016/bs.acc.2019.01.005. Epub 2019 Feb 21.
10
Hirudin as alternative anticoagulant--a historical review.水蛭素作为替代抗凝剂——历史回顾
Semin Thromb Hemost. 2002 Oct;28(5):405-14. doi: 10.1055/s-2002-35292.
引用本文的文献
1
A single-dose, four-cycle, fully repetitive crossover bioequivalence of dabigatran etexilate in Chinese.达比加群酯在中国的单剂量、四周期、完全重复交叉生物等效性研究
BMC Pharmacol Toxicol. 2025 Mar 14;26(1):62. doi: 10.1186/s40360-025-00896-1.
2
Anticoagulants utilization in eight hospitals within the Luzhou region from 2019 to 2023.2019年至2023年泸州地区八家医院抗凝剂的使用情况。
PLoS One. 2025 Jan 31;20(1):e0318463. doi: 10.1371/journal.pone.0318463. eCollection 2025.
3
Research Progress of Macromolecules in the Prevention and Treatment of Sepsis.大分子在防治脓毒症中的研究进展。
Int J Mol Sci. 2023 Aug 21;24(16):13017. doi: 10.3390/ijms241613017.
4
A Descriptive Analysis of Direct Oral Anticoagulant Drugs Dosing Errors Based on Spontaneous Reports from the EudraVigilance Database.基于欧洲药品管理局药物警戒数据库自发报告的直接口服抗凝药物剂量错误描述性分析
Pharmaceuticals (Basel). 2023 Mar 17;16(3):455. doi: 10.3390/ph16030455.
5
Polymers Inspired by Heparin and Heparan Sulfate for Viral Targeting.受肝素和硫酸乙酰肝素启发用于病毒靶向的聚合物
Macromolecules. 2022 Sep 27;55(18):7957-7973. doi: 10.1021/acs.macromol.2c00675. Epub 2022 Sep 11.
6
Potentially Inappropriate Medication Prescribing in Older Adults According to EU(7)-Potentially Inappropriate Medication List: A Nationwide Study in Portugal.根据欧盟（7）-潜在不适当用药清单评估老年人潜在不适当用药情况：葡萄牙全国性研究
Curr Ther Res Clin Exp. 2022 Jul 13;97:100681. doi: 10.1016/j.curtheres.2022.100681. eCollection 2022.
7
Critical Quality Control Methods for a Novel Anticoagulant Candidate LFG-Na by HPSEC-MALLS-RID and Bioactivity Assays.新型抗凝候选药物 LFG-Na 的高效凝胶渗透色谱-多角度激光散射-折射率检测和生物活性分析的关键质量控制方法。
Molecules. 2022 Jul 15;27(14):4522. doi: 10.3390/molecules27144522.
8
Bromelain, a Group of Pineapple Proteolytic Complex Enzymes () and Their Possible Therapeutic and Clinical Effects. A Summary.菠萝蛋白酶，一组菠萝蛋白水解复合酶及其可能的治疗和临床效果。综述。
Foods. 2021 Sep 23;10(10):2249. doi: 10.3390/foods10102249.
9
Impact of anticoagulation and antiplatelet drugs on surgery rates and mortality in trauma patients.抗凝和抗血小板药物对创伤患者手术率和死亡率的影响。
Sci Rep. 2021 Jul 26;11(1):15172. doi: 10.1038/s41598-021-94675-7.
10
Modification strategies to improve the membrane hemocompatibility in extracorporeal membrane oxygenator (ECMO).体外膜肺氧合（ECMO）中改善膜血液相容性的修饰策略。
Adv Compos Hybrid Mater. 2021;4(4):847-864. doi: 10.1007/s42114-021-00244-x. Epub 2021 May 3.
本文引用的文献
1
Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: synthesis, biological evaluation and molecular modelling.探索TGX-221相关的基于吡啶并[1,2-a]嘧啶酮的IA类PI 3-激酶抑制剂的亚型选择性：合成、生物学评价及分子模拟
Bioorg Med Chem. 2015 Jul 1;23(13):3796-808. doi: 10.1016/j.bmc.2015.03.073. Epub 2015 Apr 4.
2
Antithrombotic drugs market.抗血栓药物市场。
Nat Rev Drug Discov. 2014 Aug;13(8):571-2. doi: 10.1038/nrd4365. Epub 2014 Jul 4.
3
Efficacy and safety of a routine early invasive strategy after fibrinolysis stratified by glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: a pre-specified subgroup analysis of the TRANSFER-AMI randomised controlled trial.溶栓后常规早期侵入策略的疗效和安全性：经皮冠状动脉介入治疗中使用糖蛋白 IIb/IIIa 抑制剂的分层：TRANSFER-AMI 随机对照试验的预先指定亚组分析。
Heart. 2014 Jun;100(11):873-80. doi: 10.1136/heartjnl-2013-305231. Epub 2014 Jan 21.
4
Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation.血管血栓素前列腺素受体激活对止血、血栓形成、氧化应激和炎症的影响。
J Thromb Haemost. 2014 Feb;12(2):126-37. doi: 10.1111/jth.12472.
5
Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction.西洛他唑预防卒中研究：脑梗死二级预防的安慰剂对照双盲试验。
J Stroke Cerebrovasc Dis. 2000 Jul-Aug;9(4):147-57. doi: 10.1053/jscd.2000.7216.
6
Cangrelor: a review on pharmacology and clinical trial development.坎格雷洛：药理学与临床试验进展综述
Expert Rev Cardiovasc Ther. 2013 Oct;11(10):1279-91. doi: 10.1586/14779072.2013.837701.
7
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.2013年欧洲心脏病学会稳定型冠状动脉疾病管理指南：欧洲心脏病学会稳定型冠状动脉疾病管理特别工作组
Eur Heart J. 2013 Oct;34(38):2949-3003. doi: 10.1093/eurheartj/eht296. Epub 2013 Aug 30.
8
Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice.血小板糖蛋白IIb/IIIa抑制剂的最新进展：临床实践建议
Ther Adv Cardiovasc Dis. 2013 Aug;7(4):197-213. doi: 10.1177/1753944713487781. Epub 2013 Jul 1.
9
Application of randomized clinical trial data to actual practice: apixaban therapy for reduction of stroke risk in non-valvular atrial fibrillation patients.随机临床试验数据在实际中的应用：非瓣膜性心房颤动患者中应用阿哌沙班进行卒中预防治疗。
Curr Med Res Opin. 2013 Oct;29(10):1253-61. doi: 10.1185/03007995.2013.818967. Epub 2013 Jul 18.
10
2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.2012年美国心脏病学会基金会/美国心脏协会（ACCF/AHA）重点更新内容纳入ACCF/AHA 2007年不稳定型心绞痛/非ST段抬高型心肌梗死患者管理指南：美国心脏病学会基金会/美国心脏协会实践指南工作组报告
J Am Coll Cardiol. 2013 Jun 11;61(23):e179-347. doi: 10.1016/j.jacc.2013.01.014. Epub 2013 Apr 29.
Zotero 插件